A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2018 Planned End Date changed from 1 Aug 2017 to 1 Jul 2018.